Four major pharmaceutical investments have been paused or scrapped this year
February
AstraZeneca scraps £450m investment in Speke, Liverpool
September
AstraZeneca pauses £200m research lab in Cambridge
Manchester
Birmingham
September
Merck scraps £1bn London research centre, 125 job cuts
September
Eli Lilly pauses London Gateway lab, part of £279m investment
Plymouth
Manchester
February
AstraZeneca scraps £450m investment in Speke, Liverpool
September
AstraZeneca pauses £200m research lab in Cambridge
Birmingham
September
Merck scraps £1bn London research centre, 125 job cuts
Southampton
September
Eli Lilly pauses London Gateway lab, part of £279m investment
Plymouth
February
AstraZeneca scraps £450m investment in Speke, Liverpool
September
AstraZeneca pauses £200m research lab in Cambridge
Manchester
Birmingham
September
Merck scraps £1bn London research centre, 125 job cuts
September
Eli Lilly pauses London Gateway lab, part of £279m investment
Plymouth
Manchester
September
AstraZeneca pauses £200m research lab in Cambridge
February
AstraZeneca scraps £450m investment in Speke, Liverpool
Birmingham
September
Merck scraps £1bn London research centre, 125 job cuts
Southampton
September
Eli Lilly pauses London Gateway lab, part of £279m investment
Plymouth